Lori J. Wirth, MD

Lori J. Wirth, MD, offers advice to oncologists using lenvatinib when treating patients with differentiated thyroid cancer.

Lori J. Wirth, MD, discusses some of the unmet needs that exist in the thyroid cancer space following the FDA approval for lenvatinib for radioactive iodine-refractory differentiated thyroid cancer.

Lori J. Wirth, MD, discusses some of the emerging trends and developments that are on the horizon in the thyroid cancer space.

Lori J. Wirth, MD, discusses the role of lenvatinib following its approval from the FDA for the treatment of patients with radioactive iodine-refractory differentiated thyroid cancer.

Lori J. Wirth, MD, discusses safety data from the phase 3 SELECT trial which evaluated lenvatinib in radioactive iodine-refractory differentiated thyroid cancer.

Lori J. Wirth, MD, discusses the background and design of the phase 3 SELECT trial of lenvatinib vs placebo for the treatment of patients with radioactive iodine-refractory differentiated thyroid cancer.

Lori J. Wirth, MD, discusses some of the ongoing clinical trials investigating innovative therapies or combinations for the treatment of patients with thyroid cancer.

Lori J. Wirth, MD, discusses the outcomes of treatment with larotrectinib for patients with NTRK fusion–positive advanced thyroid cancer.

Lori J. Wirth, MD, discusses imaging techniques, biomarker identification, and promising treatments on the horizon in the thyroid cancer space.

Lori J. Wirth, MD, provides an overview on the latest advancements in diagnosis of thyroid cancer.

Lori Wirth, MD, discusses second-line treatment in relation to the patient case, and concludes the discussion with a look at emerging treatment options and the future of treating advanced RAI-refractory DTC.

An expert on thyroid cancer provides insights on treating patients with advanced RAI-refractory DTC who harbor BRAFV600E mutations.

Lori Wirth, MD, discusses molecular testing practices for patients with advanced RAI-refractory differentiated thyroid cancer.

A medical oncologist reviews real-world data on older patients with RAI-refractory DTC and provides her thoughts on treating this patient population.

An overview of the standard of care treatment for patients with advanced radioiodine-refractory differentiated thyroid cancer.

Lori Wirth, MD, discusses the safety profiles of sorafenib and lenvatinib and provides clinical insights on managing or mitigating adverse effects.

A medical oncologist provides a comprehensive overview of the current treatment options for patients with advanced RAI-refractory DTC and reviews clinical trial data on sorafenib and lenvatinib.

A leading expert on head and neck oncology provides her initial impressions on the case of a 64-year-old woman with differentiated thyroid cancer.

Lori Wirth, MD, a medical oncologist, reviews the case of a 64-year-old woman with differentiated thyroid cancer (DTC).

Dr Lori Wirth highlights remaining unmet needs and challenges in the treatment of advanced RAI-R-DTC.

Lori Wirth, MD, explains why the importance of molecular alterations in her treatment decision-making for a patient with advanced RAI-R-DTC, and the other factors she considers for an appropriate treatment.

Lori Wirth, MD, explains what regimen is considered to be the standard-of-care treatment for patients with advanced RAI-R-DTC.

Dr Lori Wirth discusses the design and data of two key clinical trials that led to the approval of the current treatment options for patients with advanced RAI-R-DTC.

Dr Lori Wirth details the common molecular alterations seen in patients with advanced RAO-R-DTC and which testing platforms she recommends.

Lori Wirth, MD, provides an overview of differentiated thyroid cancer (DTC) and radioactive iodine-refractory differentiated thyroid cancer (RAI-R-DTC).

Dr Lori Wirth reviews real-world outcomes data on lenvatinib treatment in patients with RAI-R-DTC and how they compare to the SELECT trial.

Dr Wirth reviews the updated NCCN guidelines that gave lenvatinib a category 1 recommendation for first-line treatment in advanced RAI-R-DTC and shares her experience of lenvatinib in clinical practice.

A key opinion leader explains the adverse events usually seen with lenvatinib treatment in patients with RAI-R-DTC, and the best management strategies.

Lori Wirth, MD, describes the available treatment options for patients with advanced RAI-R-DTC who progress after first-line treatment with lenvatinib.